

KABRADRUGSLIMITED

CIN-L02423MP1989PLC005438

To
Department of Corporate Services,
BSE Limited,
P J Tower, Dalal Street
Mumbai-400001

11 May 2023

Sir/ Madam,

Subject: Reconciliation of Share Capital Audit (SEBI- DP Reg.55A) for Q.E. 31.03.2023 Reference: Kabra Drugs Limited (524322).

With reference to above, we hereby enclose the Reconciliation of Share Capital Audit for quarter ended 31th March 2023 from Practicing Company Secretary.

This is for your information and record.

Thanking you,

Yours faithfully

For, KABRA DRUGS LIMITED

DIRECTOR / AUTHORISED SIGNATORY

REGD OFFC: SHOP NO. 270, SHASTRI MARKET, INDORE M.P. PHONE NO 0731-4247626

3rd May 2023 To,

BSE LIMITED

Dear Sir,

Sub: Reconciliation of Share Capital Audit Report for the quarter ended 31st March 2023

We are enclosing herewith the Reconciliation of Share Capital Audit report of M/s. KABRA DRUGS LIMITED for the quarter ended 31st March 2023.

Thanking You,

Yours faithfully,

Narasimhan Srividhya

Practicing Company Secretary



RECONCILIATION OF SHARE CAPITAL AUDIT REPORT

For Quarter Ended

31st March 2023

2 ISIN:

INE23K01017

3 Face Value:

Rs. 10/- per share

Name of the Company

KABRA DRUGS LIMITED

Registered Office Address 5

270 Shastri Market Indore MP 452007 IN

6 Correspondence Address

Same as above

Telephone & Fax Nos.

Tel.No. 0731-2971305/6501305

Email address

kabradrugs@rediffmail.com

Names of the Stock Exchanges where the company's securities are listed

Bombay Stock Exchange Ltd.

10 Issued Capital

- 11 Listed Capital (Exchange-wise) (as per company's records) Bombay Stock Exchange Ltd:
- 12 Held in dematerialized form in CDSL
- Held in dematerialized form in NSDL 13
- 14 **Physical**
- Total No. of shares (12+ 13+ 14) 15
- Reasons for difference if any, between 16 (10&11), (10&15),

Number of shares	% of Total Issued Capital		
43,88,600	100%		
11,99,607	27.33		
17,29,892 14,59,101 43,88,600	39.41 33.24 100.00%		
N.A			

Certifying the details of changes in share capital during the quarter under consideration as per Table below:

Particulars	No.of Shares	Applied /Not Applied for listing	Listed on Stock Exchanges (specify Names)	Whether intimated to CDSL	Whether intimated to NSDL	In-prin. Appr. Pending for SE (specify Names)
			Nil	 2.	<u>. </u>	

***Rights, Bonus, Preferential Issue, ESOPs, Amalgamation, Conversion, Buyback, Capital Reduction, Forfeiture, Any other (to specify).

18	Register of Members is Updated (Yes/No)	YES		
	If not, updated up to which date	Not Applicable		
19	Reference of Previous Quarter with regards to excess dematerialized shares, if any	Nil		
20	Has the company resolved the matter mentioned in Point No. 19 above in the	· ·		

Mention the total no. of requests, if any, confirmed after 21 days and the total no.of requests pending beyond 21 days with the reasons for delay:

current quarter? If not, reason why?

			J.	1
Total No. of demat requests	No. of	No of	Page	
Confirmed after 21 Days	requests Nil	Shares	Reasons for delay	
Pending for more than 21 days	Nil	Nil Nil	NA NA	-
		INII	NA	-1.



Name, Telephone and Fax No. of the Compliance officer of the Co.

Mrs.MONIKA NISHANT GATTANII, Company Secretary Ph: 022-28523437

Name, Address, Tel .& Fax No., Regn. No of the Auditor

NarasimhanSrividhya
Company Secretaries in Practice-CP.No.14058
No.52,Sundarabhavanam, 1st floor,4tha venue,
ashok nagar,chennai - 6000333
e-mail id-śrividhya0806@gmail.com
Phone No.-9791712781

Appointment of common agency for share 24 registry work If yes (name & address)

M/s. Skyline Financial Services Pvt. Ltd. A/505, Dattani Plaza, Andheri Kurla Road, Safeed Pool, Mumbai- 400072.

Any other detail that the auditor may like to provide. (e.g.BIFR Company, delisting from SE, company changed its name etc.)

-----Nil-----

Date: 03.05.2023 Place: Chennai

> Narasimhan Srividhya... Practicing Company Secretary CP No. 14058

UDIN:\\034428E000247806 Peer Review Certificate No:\\829/2020 Unique Code:\\P2004TN0\\81200

NARASIMHAN Salar LEFTYA Company Secretary In Practice Mem. No.: 34428 Cop.: 14058